The pulmonary arterial hypertension market is projected to grow significantly by 2027 owing to rising incidences of cardiovascular diseases across the globe. In addition, the expanding geriatric population is likely to further drive market growth through the forecast period.

Many cardiovascular diseases, including pulmonary arterial hypertension (PAH), have come into focus in view of the ongoing COVID-19 pandemic. The novel coronavirus has been found to cause or escalate existing heart ailments in some patients, particularly in those above the age of 65 years.

Notably, many lifestyle habits, such as smoking, drinking, and consuming packaged foods, among others, are known to contribute to pulmonary arterial hypertension. Recently, growing occurrences of PAH have become a cause for concern among governments worldwide. Subsequently, increasing research efforts towards the development of improved drugs supported by favorable government initiatives have augmented industry expansion in leading regions.

Moreover, surging focus on the development of effective therapies has been favorable for the global product landscape, thereby enhancing market dynamics. For instance, in August 2021, the Food and Drug Administration (FDA) approved the Uptravi (selexipag) injection for intravenous (IV) use in the treatment of pulmonary arterial hypertension (PAH, WHO Group I). The injection has been formulated to delay disease progression as well as lower the risk of hospitalization for PAH with WHO Functional Class II-III in adults who are temporarily unable to take oral therapy. Thus, increasing availability of targeted therapeutics has been favorable for industry growth.

The pulmonary arterial hypertension market has been categorized based on route of administration, drug class, and region. With respect to drug class, the market has further been bifurcated into vasodilators, endothelin receptor antagonist (ERA), prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), soluble guanylate cyclase (SGC) stimulators, and others.

The vasodilators drug class segment held a considerable market share in 2020 and was valued at over USD 1,365 million. Increased survival chances in critical patients with the use of vasodilators is set to propel segmental growth through the forecast period.

Based on route of administration, the market has been segregated into inhalation, oral, and intravenous. The intravenous route of administration segment held a sizeable market share in 2020 and is expected to grow at a solid pace to attain a revenue of more than USD 1,555 million by the end of 2027. Fast-acting and effective form of drug delivery provided by intravenous therapy is foreseen to facilitate segmental expansion over the study timeline.

From the regional point of view, the Middle East & Africa pulmonary arterial hypertension market was valued at around USD 124 million in 2020 and is anticipated to amass profitable gains by the end of 2027. Rising prevalence of pulmonary arterial hypertension disorder across MEA is slated to foster regional market growth through the estimated timeframe.